Tepezza Lawsuit Payout

Tepezza is an intravenous medication approved by the Food & Drug Administration (FDA) in January 2020 for the treatment of Thyroid Eye Disease (TED).

After its approval, patients began reporting hearing-related adverse effects (such as tinnitus, muffled hearing, partial or total hearing loss). Many lawsuits allege that the manufacturer, Horizon Therapeutics (formerly Horizon Pharmaceuticals), failed to adequately warn of the risk of permanent hearing damage.

These lawsuits have been consolidated into a federal multidistrict litigation (MDL) in the Northern District of Illinois, though as of now no global settlement or reported large payout has been publicly disclosed.

What Does “Payout” Mean Here?

In the context of Tepezza litigation, a “payout” can refer to either:

• A negotiated settlement between a claimant and Horizon before trial, or
• A jury verdict awarded at trial (if the case goes that far) for damages (medical costs, lost wages, pain & suffering)

Because this litigation is still in its early stage, full payout data is limited and public transparency is modest. However, legal-analyst projections give some insight into expected settlement ranges.

What Are the Estimated Settlement / Payout Ranges?

Because few (if any) reported settlements or verdicts have been finalized, most numbers are estimates based on analogous litigation, injury severity, and published law-firm prognoses. Here are representative ranges:

• One law-firm estimate: “settlements could range between $75,000 and over $200,000 per case.”
• Another estimate: “successful Tepezza settlement could be between $140,000 to $250,000.”
• A broader range: “settlement estimates range from $50,000 to over $1 million, depending on severity.”
• One more: “average estimate … around $180,000-200,000 for a successful case.”

It’s critical to emphasise: these are not guaranteed payouts. Each individual case will vary greatly depending on multiple factors.

What Factors Influence the Payout Amount?

Several key variables affect how much a claimant might receive:

1. Severity and permanence of hearing injury
   • Total or profound permanent hearing loss will command higher compensation than mild or temporary tinnitus. Analyses suggest higher valued claims when young, otherwise healthy plaintiffs suffer major irreparable injury.
2. Medical costs and future treatment needs
   • Need for hearing aids, cochlear implants, ongoing audiology, and decreased ability to work all add to the damages.
3. Strength of causal link
   • The stronger the proof that Tepezza caused the injury (versus unrelated ear disease, noise exposure, aging), the stronger the claim and higher the expected payout.
4. Age and earning capacity
   • A younger plaintiff with many working years ahead may claim higher lost-earning capacity than an older retiree.
5. Pre-existing hearing conditions
   • If the claimant already had hearing issues, the payout may be lower or the case weaker. Some law-firm estimates specifically adjust for that factor.
6. Stage of litigation, negotiation posture, and bellwether outcomes
   • As the MDL develops and bellwether trial outcomes become known, settlements or verdicts may increase or decrease accordingly.

Why Have There Been No Large Public Payouts Yet?

Despite many pending claims (200+ in MDL as of 2025), there are several reasons why major payouts or verdicts are not yet widely reported:

• The litigation is still in early stages: fact-discovery, expert reports and case-selection for bellwether trials are underway.
• Because of that, large global settlement agreements typically used in mass-tort litigation have not yet been negotiated publically.
• The first bellwether trial dates are scheduled for 2026 or later, which means the parties are in pre-trial posture and perhaps pursuing settlement talks first.

Thus while payouts are anticipated, none have yet become publicly documented. Law-firm announcements emphasise the “still early” nature of this litigation.

What Can Potential Claimants Expect?

• If you took Tepezza and subsequently suffered hearing loss, you may be eligible to file a claim. Legal websites note zero upfront cost (“no contingency fee unless you win”).
• While average settlements might cluster in the low-hundreds of thousands of dollars range, claims with significant injury and strong causation may be worth more — possibly multiple hundreds of thousands of dollars or more.
• However, you should not rely on any specific payout figure; each case is highly fact-sensitive.
• Because of the upcoming bellwether trials and evolving litigation posture, delays are likely; early resolution is not guaranteed.
• Time is also a factor: statutes of limitation apply in product-liability cases (vary by state). Prompt consulting with an attorney is advisable.

Conclusion

In summary, the Tepezza hearing‐loss litigation is generating significant interest and anticipated payouts. Although no large settlement or jury verdicts are publicly known yet, legal-analysis suggests that settlements in the range of approximately $75,000 to over $200,000 per case are plausible — with some claims (more severe injury, younger plaintiffs, strong evidence) possibly exceeding those figures.
Because the litigation is still developing (discovery underway, bellwether trials scheduled for 2026), there remains a degree of uncertainty and variability in payout outcomes. For individuals who believe they have a Tepezza-related hearing injury, it is important to consult experienced counsel soon, gather medical records carefully, and understand both the potential for compensation and the timeline involved.